These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

542 related articles for article (PubMed ID: 37129893)

  • 21. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
    Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer.
    Di Federico A; Alden SL; Smithy JW; Ricciuti B; Alessi JV; Wang X; Pecci F; Lamberti G; Gandhi MM; Vaz VR; Spurr LF; Sholl LM; Pfaff KL; Rodig SJ; Li YY; Cherniack AD; Nishino M; Johnson BE; Awad MM
    Ann Oncol; 2024 Oct; 35(10):902-913. PubMed ID: 38950679
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer.
    Frigola J; Navarro A; Carbonell C; Callejo A; Iranzo P; Cedrés S; Martinez-Marti A; Pardo N; Saoudi-Gonzalez N; Martinez D; Jimenez J; Sansano I; Mancuso FM; Nuciforo P; Montuenga LM; Sánchez-Cespedes M; Prat A; Vivancos A; Felip E; Amat R
    Mol Oncol; 2021 Apr; 15(4):887-900. PubMed ID: 33342055
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors.
    Cristescu R; Aurora-Garg D; Albright A; Xu L; Liu XQ; Loboda A; Lang L; Jin F; Rubin EH; Snyder A; Lunceford J
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101941
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer.
    Ricciuti B; Recondo G; Spurr LF; Li YY; Lamberti G; Venkatraman D; Umeton R; Cherniack AD; Nishino M; Sholl LM; Shapiro GI; Awad MM; Cheng ML
    Clin Cancer Res; 2020 Aug; 26(15):4135-4142. PubMed ID: 32332016
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A 20-gene mutation signature predicts the efficacy of immune checkpoint inhibitor therapy in advanced non-small cell lung cancer patients.
    Hu X; Guo J; Shi J; Li D; Li X; Zhao W
    BMC Pulm Med; 2023 Jun; 23(1):223. PubMed ID: 37349743
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dual Biomarker Combining DNA Damage Repair Gene Mutations and PD-L1 Expression for Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer.
    Kim H; Lim DH; Kwon YS; Kim MA; Park KU
    Anticancer Res; 2023 May; 43(5):2343-2349. PubMed ID: 37097676
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
    Dafni U; Tsourti Z; Vervita K; Peters S
    Lung Cancer; 2019 Aug; 134():127-140. PubMed ID: 31319971
    [TBL] [Abstract][Full Text] [Related]  

  • 29. T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.
    Ott PA; Bang YJ; Piha-Paul SA; Razak ARA; Bennouna J; Soria JC; Rugo HS; Cohen RB; O'Neil BH; Mehnert JM; Lopez J; Doi T; van Brummelen EMJ; Cristescu R; Yang P; Emancipator K; Stein K; Ayers M; Joe AK; Lunceford JK
    J Clin Oncol; 2019 Feb; 37(4):318-327. PubMed ID: 30557521
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Response Rates to Anti-PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase.
    Valero C; Lee M; Hoen D; Zehir A; Berger MF; Seshan VE; Chan TA; Morris LGT
    JAMA Oncol; 2021 May; 7(5):739-743. PubMed ID: 33599686
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictive values of genomic variation, tumor mutational burden, and PD-L1 expression in advanced lung squamous cell carcinoma treated with immunotherapy.
    Xu Y; Li H; Huang Z; Chen K; Yu X; Sheng J; Zhang HH; Fan Y
    Transl Lung Cancer Res; 2020 Dec; 9(6):2367-2379. PubMed ID: 33489799
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.
    Rizvi H; Sanchez-Vega F; La K; Chatila W; Jonsson P; Halpenny D; Plodkowski A; Long N; Sauter JL; Rekhtman N; Hollmann T; Schalper KA; Gainor JF; Shen R; Ni A; Arbour KC; Merghoub T; Wolchok J; Snyder A; Chaft JE; Kris MG; Rudin CM; Socci ND; Berger MF; Taylor BS; Zehir A; Solit DB; Arcila ME; Ladanyi M; Riely GJ; Schultz N; Hellmann MD
    J Clin Oncol; 2018 Mar; 36(7):633-641. PubMed ID: 29337640
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor immune microenvironment and clinical outcomes in stage IV urothelial cancer: YODO study.
    Nishiyama H; Tsuzuki T; Ohyama C; Matsuyama H; Shinozaki K; Hayashi Y; Hayashi N; Koto R; Shin E; Ogawa O
    Int J Clin Oncol; 2023 Oct; 28(10):1398-1410. PubMed ID: 37498492
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor Mutation Burden as a Potential Biomarker for PD-1/PD-L1 Inhibition in Advanced Non-small Cell Lung Cancer.
    Huang D; Zhang F; Tao H; Zhang S; Ma J; Wang J; Liu Z; Cui P; Chen S; Huang Z; Wu Z; Zhao L; Hu Y
    Target Oncol; 2020 Feb; 15(1):93-100. PubMed ID: 32052340
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The predictive power of tumor mutational burden in lung cancer immunotherapy response is influenced by patients' sex.
    Wang S; Zhang J; He Z; Wu K; Liu XS
    Int J Cancer; 2019 Nov; 145(10):2840-2849. PubMed ID: 30972745
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors.
    Manca P; Corti F; Intini R; Mazzoli G; Miceli R; Germani MM; Bergamo F; Ambrosini M; Cristarella E; Cerantola R; Boccaccio C; Ricagno G; Ghelardi F; Randon G; Leoncini G; Milione M; Fassan M; Cremolini C; Lonardi S; Pietrantonio F
    Eur J Cancer; 2023 Jul; 187():15-24. PubMed ID: 37099945
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer.
    Greally M; Chou JF; Chatila WK; Margolis M; Capanu M; Hechtman JF; Tuvy Y; Kundra R; Daian F; Ladanyi M; Kelsen DP; Ilson DH; Berger MF; Tang LH; Solit DB; Diaz LA; Schultz N; Janjigian YY; Ku GY
    Clin Cancer Res; 2019 Oct; 25(20):6160-6169. PubMed ID: 31337644
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor mutational burden as a predictive biomarker for non-small cell lung cancer treated with immune checkpoint inhibitors of PD-1/PD-L1.
    Shao MM; Xu YP; Zhang JJ; Mao M; Wang MC
    Clin Transl Oncol; 2024 Jun; 26(6):1446-1458. PubMed ID: 38190035
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer.
    Chen Y; Liu Q; Chen Z; Wang Y; Yang W; Hu Y; Han W; Zeng H; Ma H; Dai J; Zhang H
    J Exp Clin Cancer Res; 2019 May; 38(1):193. PubMed ID: 31088500
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden.
    Quintanilha JCF; Graf RP; Fisher VA; Oxnard GR; Ellis H; Panarelli N; Lin DI; Li G; Huang RSP; Ross JS; Myer PA; Klempner SJ
    JAMA Netw Open; 2023 Jan; 6(1):e2252244. PubMed ID: 36689222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.